These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 37253344)

  • 1. Clinical and Proteomic-Based Molecular Characterizations of Invasive and Noninvasive Somatotroph PitNETs.
    Chen M; Duan L; Sun W; Guo Z; Miao H; Yu N; Yang S; Wang L; Gong F; Yao Y; Zhu H
    Neuroendocrinology; 2023; 113(9):971-986. PubMed ID: 37253344
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DNA Methylation Pattern in Somatotroph Pituitary Neuroendocrine Tumors.
    Kober P; Rymuza J; Baluszek S; Maksymowicz M; Nyc A; Mossakowska BJ; Zieliński G; Kunicki J; Bujko M
    Neuroendocrinology; 2024; 114(1):51-63. PubMed ID: 37699356
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synchronous Multiple Pituitary Neuroendocrine Tumors of Different Cell Lineages.
    Mete O; Alshaikh OM; Cintosun A; Ezzat S; Asa SL
    Endocr Pathol; 2018 Dec; 29(4):332-338. PubMed ID: 30215160
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MiR-320a Acts as a Tumor Suppressor in Somatotroph Pituitary Neuroendocrine Tumors by Targeting BCAT1.
    Zhao S; Li B; Gao H; Zhang Y
    Neuroendocrinology; 2024; 114(1):14-24. PubMed ID: 37591221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemokines modulate the tumour microenvironment in pituitary neuroendocrine tumours.
    Marques P; Barry S; Carlsen E; Collier D; Ronaldson A; Awad S; Dorward N; Grieve J; Mendoza N; Muquit S; Grossman AB; Balkwill F; Korbonits M
    Acta Neuropathol Commun; 2019 Nov; 7(1):172. PubMed ID: 31703742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proteogenomic landscape and clinical characterization of GH-producing pituitary adenomas/somatotroph pituitary neuroendocrine tumors.
    Yamato A; Nagano H; Gao Y; Matsuda T; Hashimoto N; Nakayama A; Yamagata K; Yokoyama M; Gong Y; Shi X; Zhahara SN; Kono T; Taki Y; Furuki N; Nishimura M; Horiguchi K; Iwadate Y; Fukuyo M; Rahmutulla B; Kaneda A; Hasegawa Y; Kawashima Y; Ohara O; Ishikawa T; Kawakami E; Nakamura Y; Inoshita N; Yamada S; Fukuhara N; Nishioka H; Tanaka T
    Commun Biol; 2022 Nov; 5(1):1304. PubMed ID: 36435867
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytokeratin 8/18-negative somatotroph pituitary neuroendocrine tumours (PitNETs, adenomas) show variable morphological features and do not represent a clinicopathologically distinct entity.
    Soukup J; Cesak T; Hornychova H; Manethova M; Michnova L; Netuka D; Vitovcova B; Cap J; Ryska A; Gabalec F
    Histopathology; 2021 Sep; 79(3):406-415. PubMed ID: 33738859
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune Landscape of Pituitary Tumors Reveals Association Between Macrophages and Gonadotroph Tumor Invasion.
    Principe M; Chanal M; Ilie MD; Ziverec A; Vasiljevic A; Jouanneau E; Hennino A; Raverot G; Bertolino P
    J Clin Endocrinol Metab; 2020 Nov; 105(11):. PubMed ID: 32785693
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The expression of neural cell adhesion molecule and the microenvironment of pituitary neuroendocrine tumours.
    Marques P; Barry S; Carlsen E; Collier D; Ronaldson A; Grieve J; Dorward N; Mendoza N; Nair R; Muquit S; Grossman AB; Korbonits M
    J Neuroendocrinol; 2021 Dec; 33(12):e13052. PubMed ID: 34708902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transcriptomic Classification of Pituitary Neuroendocrine Tumors Causing Acromegaly.
    Rymuza J; Kober P; Rusetska N; Mossakowska BJ; Maksymowicz M; Nyc A; Baluszek S; Zieliński G; Kunicki J; Bujko M
    Cells; 2022 Nov; 11(23):. PubMed ID: 36497102
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PD-L1 Is Preferentially Expressed in PIT-1 Positive Pituitary Neuroendocrine Tumours.
    Turchini J; Sioson L; Clarkson A; Sheen A; Gill AJ
    Endocr Pathol; 2021 Sep; 32(3):408-414. PubMed ID: 33694064
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional characterization of DLK1/MEG3 locus on chromosome 14q32.2 reveals the differentiation of pituitary neuroendocrine tumors.
    Chen Y; Gao H; Liu Q; Xie W; Li B; Cheng S; Guo J; Fang Q; Zhu H; Wang Z; Wang J; Li C; Zhang Y
    Aging (Albany NY); 2020 Dec; 13(1):1422-1439. PubMed ID: 33472171
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pituitary neuroendocrine tumors with PIT1/SF1 co-expression show distinct clinicopathological and molecular features.
    Dottermusch M; Ryba A; Ricklefs FL; Flitsch J; Schmid S; Glatzel M; Saeger W; Neumann JE; Schüller U
    Acta Neuropathol; 2024 Jan; 147(1):16. PubMed ID: 38228887
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential expression levels of β-catenin are associated with invasive behavior of both functional and non-functional pituitary neuroendocrine tumor (PitNET).
    Taghavi SF; Ghorbani M; Panahi M; Nazem S; Karimi M; Salimi V; Tavakoli-Yaraki M
    Mol Biol Rep; 2023 Aug; 50(8):6425-6434. PubMed ID: 37326745
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative Acetylomics Revealed Acetylation-Mediated Molecular Pathway Network Changes in Human Nonfunctional Pituitary Neuroendocrine Tumors.
    Wen S; Li J; Yang J; Li B; Li N; Zhan X
    Front Endocrinol (Lausanne); 2021; 12():753606. PubMed ID: 34712204
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical, Biological, Radiological Pathological and Immediate Post-Operative Remission of Sparsely and Densely Granulated Corticotroph Pituitary Tumors: A Retrospective Study of a Cohort of 277 Patients With Cushing's Disease.
    Rak B; Maksymowicz M; Pękul M; Zieliński G
    Front Endocrinol (Lausanne); 2021; 12():672178. PubMed ID: 34135861
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of cholesterol metabolism-related subtypes in nonfunctioning pituitary neuroendocrine tumors and analysis of immune infiltration.
    Feng T; Hou P; Mu S; Fang Y; Li X; Li Z; Wang D; Chen L; Lu L; Lin K; Wang S
    Lipids Health Dis; 2023 Aug; 22(1):127. PubMed ID: 37563740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pituitary tumour fibroblast-derived cytokines influence tumour aggressiveness.
    Marques P; Barry S; Carlsen E; Collier D; Ronaldson A; Awad S; Dorward N; Grieve J; Mendoza N; Muquit S; Grossman AB; Balkwill F; Korbonits M
    Endocr Relat Cancer; 2019 Dec; 26(12):853-865. PubMed ID: 31645017
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is radiomics a useful addition to magnetic resonance imaging in the preoperative classification of PitNETs?
    Sathya A ; Goyal-Honavar A; Chacko AG; Jasper A; Chacko G; Devakumar D; Seelam JA; Sasidharan BK; Pavamani SP; Thomas HMT
    Acta Neurochir (Wien); 2024 Feb; 166(1):91. PubMed ID: 38376544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of kisspeptin and KISS1 receptor in pituitary neuroendocrine tumours - an immunohistochemical study.
    Mihajlovic M; Pekic S; Doknic M; Stojanovic M; Miljic D; Soldatovic I; Vukotic T; Janev T; Cirovic S; Terzic T; Raicevic S; Skender-Gazibara M; Popovic V; Manojlovic-Gacic E
    Endokrynol Pol; 2021; 72(2):91-96. PubMed ID: 33619706
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.